Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03442556 · ClinicalTrials.gov registry record · Phase 2
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency
A Phase 2 study, sponsored by University of Washington.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT03442556 is a Phase 2 study that was terminated before completion, run by University of Washington. The registered enrollment target is 18 participants.
The verdict
NCT03442556, a Phase 2 study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the growth of cancer cells, by stopping them from dividing or spreading. Rucaparib camsylate may stop the growth of tumor cells with defects in the ability to repair mistakes in DNA by forcing additional errors so that the cancer cells cannot overcome the number of errors and will then die. Giving induction docetaxel and carboplatin followed by maintenance rucaparib camsylate may work better in treating patients with castration resistant prostate cancer.
Interventions
- DRUG Carboplatin
- DRUG Docetaxel
- OTHER Laboratory Biomarker Analysis
- DRUG Rucaparib
- DRUG Rucaparib Camsylate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-08-24 |
| Est. Completion | 2025-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03442556
The ClinicalTrials.gov registry entry for NCT03442556 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT03442556 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03442556 about?
NCT03442556 is a clinical study titled "Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency". This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. ...
What is the current status of trial NCT03442556?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2018-08-24. Estimated completion is 2025-06-04.
What interventions are being tested in trial NCT03442556?
The interventions under investigation include: Carboplatin (DRUG), Docetaxel (DRUG), Laboratory Biomarker Analysis (OTHER), Rucaparib (DRUG), Rucaparib Camsylate (DRUG).
Who is sponsoring clinical trial NCT03442556?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.